Lansoprazole versus omeprazole in the treatment of reflux esophagitis
Vcev, A.; Stimac, D.; Vceva, A.; Rubinić, M.; Ivandić, A.; Ivanis, N.; Horvat, D.; Volarić, M.; Karner, I.
Acta Medica Croatica Casopis Hravatske Akademije Medicinskih Znanosti 51(3): 171-174
1997
ISSN/ISBN: 1330-0164 PMID: 9248117 Document Number: 1056
To evaluate the therapeutic potential of the newly developed proton pump inhibitor lansoprazole in patients with reflux esophagitis (grade I and II according to Savary Mueller criteria), the authors performed a single blind, randomized clinical trial comparing 20 mg omeprazole and 30 mg lansoprazole, involving 60 patients at two clinical hospitals. The treatment period was or 8 weeks, and main efficacy variables were healing of endoscopic changes and relief of reflux symptoms. No significant difference in terms of healing and relief of reflux symptoms was found either after 4 or after 8 weeks of treatment. In conclusion, 30 mg lansoprazole daily was found to be safe and effective therapy comparable to omeprazole in the short-term treatment for reflux esophagitis (grade I and II).
Document emailed within 1 workday
